Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2012

01.06.2012 | Original Article

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck

verfasst von: Anna-Maria A. De Costa, Corinne A. Schuyler, David D. Walker, M. Rita I. Young

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

While studies have indicated that squamous cell carcinoma of the head and neck (HNSCC) is associated with immune suppression, these studies did not analyze the immune response at the dysplastic stage. The present study utilized a mouse model of 4-nitroquinoline 1-oxide-induced oral carcinogenesis to examine the alterations in immune phenotype at the premalignant and malignant stages of HNSCC. Cervical lymph nodes of HNSCC-bearing mice were found to contain a greater number of cells, including a greater number of conventional (Tconv) and regulatory (Treg) T cells, compared to cervical lymph nodes of control and premalignant lesion-bearing mice, though the Tconv cells appear to be less proliferative and the Treg cells appear to be less suppressive at the HNSCC stage. Premalignant lesion-bearing mouse lymph nodes consist of a greater percentage of Tconv cells expressing markers for activation, memory, and exhaustion compared to both control and HNSCC-bearing mice. Also, lymph nodes’ cells from both premalignant lesion-bearing and HNSCC-bearing mice include increased levels of Th1, Tc1, and Th17 cells, with no differences in levels of Th2 cells, compared to control mice. The data show that while there is the expected increase in immunosuppressive Tregs in lymph nodes when HNSCC is present, there is also an unexpected increase in immune populations usually associated with a beneficial antitumor response, including Tconv cells and Th1 and Tc1 cells. In addition, the results demonstrate that the premalignant stage of HNSCC development is associated with a robust immune response involving an increase in inflammatory Th1, Tc1, and Th17 cells.
Literatur
3.
Zurück zum Zitat King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, Worthington HV, Thornhill MH (1995) Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 332(16):1052–1057. doi:10.1056/NEJM199504203321602 PubMedCrossRef King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, Worthington HV, Thornhill MH (1995) Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 332(16):1052–1057. doi:10.​1056/​NEJM199504203321​602 PubMedCrossRef
4.
Zurück zum Zitat Harris JP, Penn I (1981) Immunosuppression and the development of malignancies of the upper airway and related structures. Laryngoscope 91(4):520–528PubMedCrossRef Harris JP, Penn I (1981) Immunosuppression and the development of malignancies of the upper airway and related structures. Laryngoscope 91(4):520–528PubMedCrossRef
5.
Zurück zum Zitat Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R (2008) Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8:10PubMed Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R (2008) Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8:10PubMed
6.
Zurück zum Zitat Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14(12):3706–3715. doi:10.1158/1078-0432.CCR-07-5126 PubMedCrossRef Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14(12):3706–3715. doi:10.​1158/​1078-0432.​CCR-07-5126 PubMedCrossRef
7.
Zurück zum Zitat Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2):465–472. doi:10.1158/1078-0432.CCR-05-1886 PubMedCrossRef Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2):465–472. doi:10.​1158/​1078-0432.​CCR-05-1886 PubMedCrossRef
8.
Zurück zum Zitat Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69–74PubMedCrossRef Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69–74PubMedCrossRef
9.
Zurück zum Zitat Lathers DM, Achille NJ, Young MR (2003) Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64(12):1160–1166PubMedCrossRef Lathers DM, Achille NJ, Young MR (2003) Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64(12):1160–1166PubMedCrossRef
10.
Zurück zum Zitat Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH (2009) Preclinical models of HPV+ and HPV− HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31(7):911–918. doi:10.1002/hed.21040 PubMedCrossRef Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH (2009) Preclinical models of HPV+ and HPV− HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31(7):911–918. doi:10.​1002/​hed.​21040 PubMedCrossRef
11.
Zurück zum Zitat Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA (2007) Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 86(8):506–511PubMed Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA (2007) Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 86(8):506–511PubMed
12.
Zurück zum Zitat Zeng X, Chen Q, Nie M (2003) The relationship of Fas and Fas L protein expression in oral carcinogenesis. Hua Xi Kou Qiang Yi Xue Za Zhi 21(4):259–262PubMed Zeng X, Chen Q, Nie M (2003) The relationship of Fas and Fas L protein expression in oral carcinogenesis. Hua Xi Kou Qiang Yi Xue Za Zhi 21(4):259–262PubMed
15.
Zurück zum Zitat Strati K, Pitot HC, Lambert PF (2006) Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103(38):14152–14157. doi:10.1073/pnas.0606698103 PubMedCrossRef Strati K, Pitot HC, Lambert PF (2006) Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103(38):14152–14157. doi:10.​1073/​pnas.​0606698103 PubMedCrossRef
16.
Zurück zum Zitat O’Malley BW Jr, Cope KA, Johnson CS, Schwartz MR (1997) A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 123(1):20–24PubMedCrossRef O’Malley BW Jr, Cope KA, Johnson CS, Schwartz MR (1997) A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 123(1):20–24PubMedCrossRef
17.
Zurück zum Zitat Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, Goon PK (2011) Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 268(11):1541–1547. doi:10.1007/s00405-011-1714-8 PubMedCrossRef Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, Goon PK (2011) Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 268(11):1541–1547. doi:10.​1007/​s00405-011-1714-8 PubMedCrossRef
18.
Zurück zum Zitat Verastegui E, Morales R, Barrera JL, Mueller A, Guzman B, Meneses A, Alfaro G (2002) Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol 102(1):37–47. doi:10.1006/clim.2001.5130 PubMedCrossRef Verastegui E, Morales R, Barrera JL, Mueller A, Guzman B, Meneses A, Alfaro G (2002) Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol 102(1):37–47. doi:10.​1006/​clim.​2001.​5130 PubMedCrossRef
20.
Zurück zum Zitat Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175–2186. doi:10.1084/jem.20100637 PubMedCrossRef Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175–2186. doi:10.​1084/​jem.​20100637 PubMedCrossRef
22.
Zurück zum Zitat Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213–221PubMedCrossRef Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213–221PubMedCrossRef
23.
Zurück zum Zitat Rosshart S, Hofmann M, Schweier O, Pfaff AK, Yoshimoto K, Takeuchi T, Molnar E, Schamel WW, Pircher H (2008) Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur J Immunol 38(12):3354–3364. doi:10.1002/eji.200838690 PubMedCrossRef Rosshart S, Hofmann M, Schweier O, Pfaff AK, Yoshimoto K, Takeuchi T, Molnar E, Schamel WW, Pircher H (2008) Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur J Immunol 38(12):3354–3364. doi:10.​1002/​eji.​200838690 PubMedCrossRef
26.
Zurück zum Zitat Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B (2010) Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 103(8):1245–1254. doi:10.1038/sj.bjc.6605891 PubMedCrossRef Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B (2010) Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 103(8):1245–1254. doi:10.​1038/​sj.​bjc.​6605891 PubMedCrossRef
27.
Zurück zum Zitat Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, Sanchez-Madrid F (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 178(2):537–547PubMedCrossRef Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, Sanchez-Madrid F (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 178(2):537–547PubMedCrossRef
28.
Zurück zum Zitat Poulton TA, Gallagher A, Potts RC, Beck JS (1988) Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology 64(3):419–425PubMed Poulton TA, Gallagher A, Potts RC, Beck JS (1988) Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology 64(3):419–425PubMed
29.
Zurück zum Zitat Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Alikhan S, Plunkett FJ, Masters JE, Jackson S, Griffiths SJ, Pircher HP, Soares MV, Akbar AN (2009) KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 113(26):6619–6628. doi:10.1182/blood-2009-01-199588 PubMedCrossRef Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Alikhan S, Plunkett FJ, Masters JE, Jackson S, Griffiths SJ, Pircher HP, Soares MV, Akbar AN (2009) KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 113(26):6619–6628. doi:10.​1182/​blood-2009-01-199588 PubMedCrossRef
30.
Zurück zum Zitat Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP (2005) Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 174(10):6088–6094PubMed Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP (2005) Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 174(10):6088–6094PubMed
31.
Zurück zum Zitat Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350–354. doi:10.1038/nature05115 PubMedCrossRef Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350–354. doi:10.​1038/​nature05115 PubMedCrossRef
32.
Zurück zum Zitat Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215–4225. doi:10.1128/JVI.02844-06 PubMedCrossRef Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215–4225. doi:10.​1128/​JVI.​02844-06 PubMedCrossRef
33.
Zurück zum Zitat Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, Kato S, Yoshimura A (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203(6):1391–1397. doi:10.1084/jem.20060436 PubMedCrossRef Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, Kato S, Yoshimura A (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203(6):1391–1397. doi:10.​1084/​jem.​20060436 PubMedCrossRef
35.
Zurück zum Zitat Reiners JJ Jr, Rupp T, Colby A, Cantu AR, Pavone A (1989) Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model. Cancer Res 49(5):1202–1206PubMed Reiners JJ Jr, Rupp T, Colby A, Cantu AR, Pavone A (1989) Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model. Cancer Res 49(5):1202–1206PubMed
37.
Zurück zum Zitat Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238. doi:10.1038/nature04753 PubMedCrossRef Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238. doi:10.​1038/​nature04753 PubMedCrossRef
Metadaten
Titel
Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck
verfasst von
Anna-Maria A. De Costa
Corinne A. Schuyler
David D. Walker
M. Rita I. Young
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1154-8

Weitere Artikel der Ausgabe 6/2012

Cancer Immunology, Immunotherapy 6/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.